Germany

CureVac

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

CureVac Nets EU Funding to Ramp up Vaccine Production

Lead Product(s): mRNA-based vaccines

Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: European Investment Bank

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 06, 2020

Details:

The EIB loan will support CureVac’s activities to complete its new messenger ribonucleic acid (mRNA) production facility in Tübingen, Germany.

CureVac

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

CureVac Taps Tesla for 'RNA Microfactories,' Elon Musk Says

Lead Product(s): mRNA-based vaccines

Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Tesla

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 02, 2020

Details:

CureVac has reportedly snared a big partner to help build its game-changing RNA "printers" that could turn global interest back in its favor.

BioNTech SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Temasek Leads a $250M Raise for BioNTech as First Covid-19 mRNA Vaccine Data Looms

Lead Product(s): mRNA vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Temasek

Deal Size: $250.0 million Upfront Cash: $139.0 million

Deal Type: Funding June 29, 2020

Details:

BioNTech is expected to post data from its Phase I/II trial virtually any day now, as analysts expect some hard numbers on immunogenicity and safety for BNT162 in the June/July time frame.

CureVac

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

CureVac Gets Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate

Lead Product(s): mRNA vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 17, 2020

Details:

German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for CureVac's vaccine program to prevent SARS-CoV-2 infection.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

CureVac

CureVac Nets EU Funding to Ramp up Vaccine Production

CureVac

CureVac Taps Tesla for 'RNA Microfactories,' Elon Musk Says

BioNTech SE

Temasek Leads a $250M Raise for BioNTech as First Covid-19 mRNA Vaccine Data Looms

CureVac

CureVac Gets Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate